Bioequivalency, Gene, RNA and Vaccine - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioequivalency

Gene

RNA

Vaccine

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Worldwide Clinical Trials

MAY 30, 2024

Approval has been based on bioequivalence with the FDA stating that the effectiveness of Radicava ORS is based on a study showing comparable levels of Radicava ORS in the bloodstream to the levels from the IV formulation of Radicava. This is administered according to the same treatment regimen as for the IV infusion.

Gene

Gene Clinical Trials Clinical Trials Gene Therapy

Clinical Catch-Up: December 21-25 | BioSpace

The Pharma Data

DECEMBER 27, 2020

Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. CureVac and the University Medical Center of Mainz launched a Phase III trial of CVnCoV, their COVID-19 vaccine candidate, in healthcare workers. The drug is an autologous IL13Ralpha2-CAR-T cell product.

Trials

Trials Antibody Gene Therapy Clinical Trials

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Clinical Catch-Up: December 21-25 | BioSpace

Stay Connected